Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity
Open Access
- 13 February 2017
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature Communications
- Vol. 8 (1), 14340
- https://doi.org/10.1038/ncomms14340
Abstract
Emerging data suggest that locoregional cancer therapeutic approaches with oncolytic viruses can lead to systemic anti-tumour immunity, although the appropriate targets for intratumoral immunomodulation using this strategy are not known. Here we find that intratumoral therapy with Newcastle disease virus (NDV), in addition to the activation of innate immunity, upregulates the expression of T-cell co-stimulatory receptors, with the inducible co-stimulator (ICOS) being most notable. To explore ICOS as a direct target in the tumour, we engineered a recombinant NDV-expressing ICOS ligand (NDV-ICOSL). In the bilateral flank tumour models, intratumoral administration of NDV-ICOSL results in enhanced infiltration with activated T cells in both virus-injected and distant tumours, and leads to effective rejection of both tumours when used in combination with systemic CTLA-4 blockade. These findings highlight that intratumoral immunomodulation with an oncolytic virus expressing a rationally selected ligand can be an effective strategy to drive systemic efficacy of immune checkpoint blockade.Keywords
This publication has 47 references indexed in Scilit:
- Immunologic Correlates of the Abscopal Effect in a Patient with MelanomaThe New England Journal of Medicine, 2012
- Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8α+ dendritic cellsThe Journal of Experimental Medicine, 2011
- Type I interferon is selectively required by dendritic cells for immune rejection of tumorsThe Journal of Experimental Medicine, 2011
- B7-H2 Is a Costimulatory Ligand for CD28 in HumanImmunity, 2011
- Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical TrialClinical Cancer Research, 2010
- Interference of CD40L-Mediated Tumor Immunotherapy by Oncolytic Vesicular Stomatitis VirusHuman Gene Therapy, 2010
- T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapyBlood, 2009
- Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonistsClinical and Experimental Immunology, 2009
- The costimulatory molecule ICOS regulates the expression of c-Maf and IL-21 in the development of follicular T helper cells and TH-17 cellsNature Immunology, 2008
- CTLA-4 blockade increases IFNγ-producing CD4 + ICOS hi cells to shift the ratio of effector to regulatory T cells in cancer patientsProceedings of the National Academy of Sciences of the United States of America, 2008